# A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer

> **NCT04144517** · PHASE2 · COMPLETED · sponsor: **Mural Oncology, Inc** · enrollment: 14 (actual)

## Conditions studied

- Squamous Cell Carcinoma of Head and Neck

## Interventions

- **DRUG:** Nemvaleukin Alfa
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04144517
- **Lead sponsor:** Mural Oncology, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-05
- **Primary completion:** 2021-10-08
- **Final completion:** 2022-01-07
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04144517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04144517, "A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04144517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*